Division of Agenus Inc.
Latest From 4-Antibody AG
Biotechnology companies and their investors came back from summer break with a slew of venture capital funding rounds and a royalty deal, although it remains to be seen how many early-stage firms will remain financially independent with large biotech and pharmaceutical companies raising massive stockpiles of cash.
Amgen moves into the chimeric antigen receptor T-cell space in cancer under a complex partnership with Kite Pharma. Gilead, Isis and Janssen agree to multiple deals during and after the holiday season, while scuttled deals return assets or rights to Vanda, AMAG and OncoGenex.
Incyte will pay Agenus $60m up front and $350m in development, regulatory and commercial milestone fees to license the Retrocyte Display antibody discovery platform for the development of novel immunotherapies. The upfront fee is comprised of a $25m technology and program access fee as well as a $35m equity investment at $4.51 per share.
- Drug Discovery Tools
- Synthesis Technologies, Production Processes
- Therapeutic Areas
- Infectious & Viral Diseases
- Western Europe
- Parent & Subsidiaries
- Agenus Inc.
- Senior Management
Robert F Burns, PhD, CEO
Luis Martin-Parras, PhD, Head, R&D & Admin.
Andreas Richter, Fin. Consultant
- Contact Info
Phone: (41) 61 633 22 60
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.